Abstract: A neural network training method and apparatus and an image matching method and apparatus are provided. The neural network training method at least includes: labeling annotation information of a first clothing instance and a second clothing instance, where the first clothing instance and the second clothing instance are respectively from a first clothing image and a second clothing image; pairing the first clothing image and the second clothing image in response to a state of matching between the first clothing instance and the second clothing instance; and training a neural network to be trained based on the paired first clothing image and second clothing image.

Abstract: Disclosed is an application of a series of dimethylphosphine oxide compounds in the preparation of an LRRK2 kinase activity inhibitor-related drug, specifically an application of the compound shown in formula (I) or a pharmaceutically acceptable salt thereof in the preparation of an LRRK2 kinase activity inhibitor-related drug.

Abstract: Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.

Abstract: An image processing method and apparatus, and a storage medium are provided. The method includes: obtaining a first feature map of an image to be processed (S101); determining a final weight vector of the first feature map (S102); determining a target normalization mode corresponding to the first feature map from a preset normalization set is determined according to the final weight vector (S103); and normalizing the first feature map by means of the target normalization mode to obtain a second feature map (S104).

Abstract: Disclosed is an application of a series of dimethylphosphine oxide compounds in the preparation of an LRRK2 kinase activity inhibitor-related drug, specifically an application of the compound shown in formula (I) or a pharmaceutically acceptable salt thereof in the preparation of an LRRK2 kinase activity inhibitor-related drug.

Abstract: The present disclosure relates to a series of tricyclic compounds and the use thereof as receptor agonists of sphingosine-1-phosphate subtype 1 (S1P1), and in particular relates to compounds as shown in formula (I) or pharmaceutically acceptable salts thereof.

Abstract: The present disclosure relates to an information processing method and apparatus, an electronic device, and a storage medium. The method includes: inputting received input information into a neural network; processing the input information by means of the neural network, where in the case that convolution processing is executed by means of a convolution layer of the neural network, a convolution kernel of the convolution layer is updated by using a transformation matrix configured for the convolution layer, so that the convolution processing of the convolution layer is completed by means of the updated convolution kernel; and outputting a processing result of the processing of the neural network. According to embodiments of the present disclosure, group convolution of a neural network in any form can be implemented.

Abstract: A cyclopropylamine compound as a lysine-specific demethylase 1 (LSD1) inhibitor. Particularly, the present invention relates to a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. The present invention also provides an application of the same in preparing a drug for treating an LSD1-related disease.

Abstract: Provided are a crystal form of a tricyclic compound and a preparation process thereof. Also provided is an application of the crystal form in preparing a drug for treating a disease related to a sphingosine-1-phosphate subtype 1 (S1P1) receptor.

Abstract: Embodiments of the present disclosure disclose normalization methods and apparatuses for a deep neural network, devices, and storage media. The method includes: inputting an input data set into a deep neural network, the input data set including at least one piece of input data; normalizing a feature map set output by means of a network layer in the deep neural network from at least one dimension to obtain at least one dimension variance and at least one dimension mean; and determining a normalized target feature map set based on the at least one dimension variance and the at least one dimension mean. Based on the embodiments of the present disclosure, normalization is performed along at least one dimension so that statistics information of each dimension of a normalization operation is covered, thereby ensuring good robustness of statistics in each dimension without excessively depending on the batch size.

Abstract: Disclosed are a class of isoquinoline compounds acting as RHO protein kinase inhibitors, and the use thereof in the preparation of a drug for treating diseases associated with RHO protein kinase. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof.

Abstract: Disclosed is a class of new aryl-phosphorus-oxygen compounds as shown in formula (I) as EGFR kinase inhibitors, and pharmaceutically acceptable salts thereof.

Abstract: Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.

Abstract: The present disclosure relates to a series of tricyclic compounds and the use thereof as receptor agonists of sphingosine-1-phosphate subtype 1 (S1P1), and in particular relates to compounds as shown in formula (I) or pharmaceutically acceptable salts thereof.

Abstract: The invention discloses a crystal form A of a compound (I) and a preparation method thereof, and further discloses an application of the crystal form A as a PDE2 or TNF-? inhibitor.

Abstract: Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNF? inhibitors, in particular, the compounds as shown in formula (I), or tautomers thereof or pharmaceutically acceptable salts thereof.

Abstract: The invention discloses a crystal form A of a compound (I) and a preparation method thereof, and further discloses an application of the crystal form A as a PDE2 or TNF-? inhibitor.

Abstract: Hydroxyl purine compounds represented by formula (I), tautomers or pharmaceutically acceptable salts thereof, and applications thereof as PDE2 or TNF-? inhibitors.

Abstract: Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNF? inhibitors, in particular, the compounds as shown in formula (I), or tautomers thereof or pharmaceutically acceptable salts thereof.

Abstract: The present invention discloses a class of isoquinolinesulfonyl derivatives as RHO kinase inhibitors, and pharmaceutical compositions thereof, and relates to pharmaceutically acceptable uses thereof. Specifically, the present invention relates to a compound as represented by formula (I), or a pharmaceutically acceptable salt thereof.